FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

Drew Armstrong

Executive Editor

Peter Marks, the head of the FDA’s Center for Biologics Evaluation and Research and one of the agency’s highest-profile officials, has suddenly resigned amid a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

Drew Armstrong

Executive Editor

Sign up to read this article for free.

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

AstraZeneca CEO says Europe is 'falling behind' on R&D and manufacturing investments

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA's Pe­ter Marks re­signs, says he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Drew Armstrong

Executive Editor

Sign up to read this article for free.

Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Large vac­cine mak­ers stand by their in­vest­ments de­spite US head­winds

With aims to be­come a 'gen­er­a­tional biotech,' Zealand Phar­ma hires Lil­ly vet­er­an as sci­ence chief

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

As­traZeneca CEO says Eu­rope is 'falling be­hind' on R&D and man­u­fac­tur­ing in­vest­ments

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

FDA's Peter Marks resigns, says he won't accept Kennedy's 'misinformation and lies'

China’s biotech market is staging a comeback that US biotech can only wish for

Large vaccine makers stand by their investments despite US headwinds

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

AstraZeneca CEO says Europe is 'falling behind' on R&D and manufacturing investments

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence